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Abstract
The Cancer Genomics and Biology 2015 meeting embodied a three way
collaboration among colleagues from the Global Cancer Genomics Consortium (GCGC),
the Unifaith Cancer Institute China and Jiujiang University of China. The meeting
marks the fifth and the last meeting of GCGC, which was formed in 2010. Previous
four GCGC meetings have been held at the Tata Memorial Center- Mumbai, Institute
of Molecular Medicine-Lisbon, and Graduate Medical School Kyoto University-Kyoto.
In contrast to the genomic themes of the previous meetings, the 2015 conference
theme was at the interface of laboratory and translation research and emerging
therapeutics as reflected in the shared interests of all three collaborative entities –
Cancer Genomics and Biology 2015. This year’s conference was co-organized by the
Jiujiang University at the Run Run Shaw building, Jiujiang University, Jiujiang City,
China, on November 13 and 14, 2015. The conference attracted over 174 participants
with 13 platform presentations. Scientific sessions included a plenary and five platform
scientific sessions with themes ranging from biomarkers, stem cells and markers
of the tumor microenvironment, proteomics and epigenetics, big data, to hormone
and expression profiles. The meeting concluded with closing remarks by conference
co-chairs emphasizing with the need to broaden membership across the globe,
establishing priorities, and redrafting a white paper to launch a new consortium.
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Introduction

biology insights in medical education, training, research
and clinical care at the Affiliated Hospital of Jiujiang
University. Scientific sessions included a plenary and five
platform scientific sessions with themes that included: 1)
biomarkers; 2) two sessions on stem cells and markers
of the tumor microenvironment; 3) proteomics and
epigenetics; 4) big data; and 5) hormone and expression
profiles. The meeting was concluded with closing remarks
by Professors Chow, Kumar and Yang, and a discussion
about the changing mission of the consortium, the need
to integrate additional oncologists and cancer scientists
across the world by re-drafting a consortium white paper,
and discussed the venue and host of the 2016 meeting.

The recently concluded Cancer Genomics
and Biology 2015 meeting (CGB 2015) embodied a
meaningful collaboration among colleagues from the
Global Cancer Genomics Consortium (GCGC), the
Unifaith Cancer Institute and Jiujiang University from
China. The meeting was particularly rewarding as it was
to mark the 5th consecutive annual GCGC meeting but
this time by spreading its wings to China by promoting
collaborations in Cancer Genomics and Biology through
three-ways partnership with the Unifaith Cancer Institute
and Jiujiang University. The GCGC is an international
organization founded by scientists, cryptographer,
physician scientists and oncologists from five institutions –
the School of Medicine and Health Sciences of the George
Washington University, USA; the Kyoto University
Graduate School of Medicine, Japan; the Rajiv Gandhi
Center for Biotechnology, India; the Tata Memorial
Centre, India; the Institute of Molecular Medicine,
Hospital de Santa Maria, Portugal; and the Structural
Genomic Consortium at the University of Oxford, UK.
Previous four GCGC meetings have been held at the
Tata Memorial Center- Mumbai, Institute of Molecular
Medicine-Lisbon, and Graduate Medical School Kyoto
University-Kyoto. The CGB 2015 was also special as
it represented the last meeting of the GCGC which was
formed in December 2010 for a period of five years. The
meeting was also part of a new chapter with additional
colleagues from around the globe by relaunching a
modified consortium in 2016 to reflect changing horizons,
the nature of scientific questions and available shared
resources, and professional interests of our colleagues.
This year’s conference was co-organized by the Jiujiang
University at the Run Run Shaw building, Jiujiang
University, Jiujiang City, China, on November 13 and 14,
2015. The conference attracted over 10 overseas and 164
Chinese domestic participants and included 13 invited
platform presentations.

Biomarkers
The meeting started with an opening plenary
presentation on “Prognostic biomarkers in metastatic
breast cancer” by Professor Luis Costa from Lisbon
Medical Academic Center Portugal. Dr. Costa started
by highlighting the value of understanding the most
important limitations in the treatment of breast cancer the development of resistance against most commonly
used endocrine and HER2-directed therapies and
associated predictive biomarkers. He presented data from
the BOLERO-2 study showing that the combined use of
mTOR inhibitor everolimus and exemestane in second
line treatment of aromatase inhibitor resistant breast
cancer lead to an increased time to progression, suggesting
reversal of resistance. He also shared his own data showing
a positive correlation between the levels of pS6 kinase, a
biomarker of mTOR activity, with survival in metastatic
BC patients [1]. Per Dr. Costa, inhibition of CDK4/6 by
palbociclib is also effective in reversing or preventing
endocrine resistance and increasing time to progression
in metastatic breast cancer patients upon combining with
the aromatase inhibitor letrozole. However, he pointed out
that we do not have yet a biomarker to select the patients
for CDK4/6 inhibition. Regarding resistance to HER2directed trastuzumab therapy, Dr. Costa reminded the
audience of the unprecedented results of the CLEOPATRA
study (i.e. superior overall survival when pertuzumab is
added to trastuzumab and docetaxel) and the efficacy of
T-DM1 for trastuzumab and lapainib resistant disease.
Dr. Costa was also excited about the recently reported
association of the high levels of stromal tumor-infiltrating
lymphocytes with the lack of benefit from adjuvant
trastuzumab but wondered about the validity of this finding
in metastatic patients. Besides he shared recent findings
from his lab showing an association between RANK’s
missense SNPs and prognosis of breast cancer patients
with bone metastases and suggested an increased overall
survival of patients with homozygous polymorphisms
compared to those with heterozygous ones [2]. Dr. Costa
closed his presentation by emphasizing that there is a need
to support clinical decisions with biomarkers as predictive

Focus on the Cancer Genomics, Biology and
Cancer Patient Care
In contrast to the genomic themes of the previous
meetings, the 2015 conference theme was at the interface
of laboratory and translation research and emerging
therapeutics as reflected in the shared interests of all
three collaborative entities – Cancer Genomics and
Biology 2015. The conference was opened by its CoChairman Professor Yao-fang Yang, Vice President
Jiujiang University with a brief synopsis of the academic
and scholarly activities and clinical medicine at the
University. Prof. Yang also introduced the other two
conference Co-Chairs Professor Louis Chow and
Professor Rakesh Kumar, and highlighted the role played
by newly developed research methodologies and cancer
www.impactjournals.com/Genes&Cancer
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indicators of treatment response or resistance.
Professor Rakesh Kumar from the George
Washington University started his plenary lecture by
elaborating on the significance of extra- and intra-cellular
milieu in modifying the genome through chromatin
remodeling and specifically discussed the value of
targeting the MTA1 master chromatin remodeler, one of
the most frequently up-regulated oncogenes in human
cancer [3]. MTA1 up-regulation correlates with an
aggressive and invasive tumor phenotypes and unfavorable
outcome for cancer patients. At the cellular level, MTA1containing chromatin remodeling complexes regulate a
range of processes including, cell survival, invasiveness,
transformation, DNA-damage response, angiogenesis,
metastasis and therapeutic sensitivity of tumor cells.
Dr. Kumar also discussed the role of MTA1-containing
chromatin remodeling complexes as a hub to modify the
expression of genes with functions in embryonic stemcell differentiation, reprogramming of pluripotent stem
cells and mesenchymal as well as cancer stem cells.
Furthermore, Dr. Kumar shared recent literature about the
contribution of MTA1 in modifying the chemo-sensitivity
of cancer cells in experimental model systems. Dr. Kumar
also presented a brief summary of advances in the past
two decades since the discovery of MTA1 and shared his
view about the yet to be realized progress in the area of
MTA1 in cancer biology and treatment. He concluded
his presentation by highlighting the roles of signaldependent combinatorial post-translational modifications
of MTA1 in determining the nature of resulting MTA1contaning chromatin remodeling complexes and selection
of downstream target genes [4]. Finally, he discussed how
selective recognition or targeting of such post-translational
modifications of MTA1 could serve as superior biomarkers
and targets in cancer.
Professor Da-Qiang Li from the Fudan University
Shanghai Cancer Center highlighted the role of the ringbetween-ring (RBR) family of E3 ubiquitin ligases in
breast cancer progression. He found that one of ringfinger proteins (RNFs) is significantly down-regulated
in human breast tumors as compared to its level in the
matched adjacent noncancerous tissues, and predicts a
better survival of breast cancer patients. Further analysis
revealed that this molecule is largely silenced by DNA
methylation of the putative CpG island and that treatment
with the DNA methylation inhibitor or knockdown of the
methyl-binding protein 4 (MBD4) activates the expression
of this RNF. The remainder of Dr. Li’s presentation was
focused on the underlying the nature of its downstream
substrate(s) that might be responsible for the noted
mechanism of action of this RNF in human cancer.
Interestingly, Dr. Li was able to examine the status of this
RNF as well as its putative substrate in primary breast
cancer patients. Dr. Li concluded his presentation by
establishing the significance of epigenetically silencing
of a ligase in breast cancer progression and the value of
www.impactjournals.com/Genes&Cancer

various components of this pathway as biomarkers.

Stem Cells and
Microenvironment

Markers

of

Tumor

The highlights of the session included insightful
discussion on the latest advances in Asian Cancer
Genomics and their implication in our understanding
and management of human cancer by Dr. Bin-Tean Teh
from the National Cancer Center Singapore. The core of
Dr. Teh approach resides in high-throughput technologies
to ask complex yet relevant cancer genomic questions
using the appropriate tumor specimens, and take these
findings back to the patients by correlating them with
clinicopathological variables and discover new therapeutic
targets and biomarkers for the benefits of cancer patients.
Dr. Teh used fibroepithelial breast tumors as an example
to illustrate the approach taken by his team and how they
discovered MED12 and RARA as frequently mutated
genes in this group of tumors [5]. The second part of
Dr. Teh’s presentation was focused on the genetics of
pathogen- or no-pathogen driven cholangiocarcinomas,
and its impact on pathogenesis of the disease [6]. In
the last segment of his presentation, Dr. Teh shared their
very exciting studies on herbal carcinogenesis based on
the association of Aristolochic Acid and the development
of upper urinary tract urothelial cancer in certain Asian
population. Finally, Dr. Teh highlighted the need to start
using genomic biomarkers for screening individuals who
might be susceptible to certain cancers.
Dr. Feng Gu from the Tianjin Medical University
Cancer Institute and Hospital discussed the role of tumor
microenvironment in tumor initiation and progression
via supporting the cell proliferation, self-renewal
capacity, immune evasion, and apoptotic resistance. In
addition, he pointed out that the research of tumor should
focus on a combined mechanism including the tumor
microenvironment. Dr. Gu also discussed the merit of
using a 3-D tumor model over 2-D cell culture system
to simulate the tumor microenvironment using primary
culture systems. He finished the discussion by focussing
on multifactorial contribution of the network of tumor cell
signaling and extracellular signaling in regulating cancer
cell migration and metastasis.
Dr. Asha Nair from the Rajiv Gandhi Centre for
Biotechnology Trivandrum discussed the contribution of
cancer stem cells in the recurrence of colorectal cancer
patients who have undergone surgical resection. The
focus of her presentation was on the surgical margins and
how one best can decide the optimal distal margin to be
removed to minimize tumor recurrence. She argued that “a
negative distal margin could be crucial for reducing risk of
local and distant recurrence and post-surgery life of CRC
patients.” In this context, Dr. Nair explored the molecular
signatures and biomarkers that could be potentially used to
make a decision about the resection length. Data presented
3
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suggest the feasibility of collecting enriching cancer stem
cell population, i.e. CD133, CD44, EpCAM positive, from
clinical CRC specimens through FACS. The team found
that distal surgical margins are enriched with EpCAM/
CD133 positive cells as compared to normal counterpart.
Interestingly such cells in distal surgical margins also
express drug resistance genes in some cases. Dr. Nair
closed her presentation by suggesting that distal tumor
margins may represent a safe niche for cancer stem cells
and drug resistance cells – both important in disease
recurrence. Therefore, Dr. Nair shared her experience in
providing critical biomarker-based information to surgical
oncologists to make an informed decision of the surgical
length to be removed as they operate on CRC cancer
patients.
Professor Xin-Yuan Guan from The University of
Hong Kong presented a fascinating example of reversal
of non-cancer stem cells into cancer stem cells by
reprogramming through ATOH8 atonal helix-loop-helix
transcription factor. He noted an overall ATOH8 downregulation in hepatocellular carcinomas and these events
are associated with poor differentiation and diseasefree survival, and carried out functional study to show
a tumor suppressive nature of ATOH8 [7]. Dr. Guan
found that ATOH8 may be a board repressor of stemnessassociated genes such as OCT4, NANOG and CD133, and
accordingly, the loss of ATOH8 in CD133+ cancer stem
cell population with ability to self-renew, differentiate and
resist chemotherapy. Consistent of these observations, Dr.
Guan presented additional evidence showing that ATOH8
depletion may lead to a better generation of induced
pluripotent stem cells. In brief, Dr. Guan suggested that
CD133 negative cells could be reprogrammed to destine
into CD133+ cancer stem cells by modifying the levels of
ATOH8; and conversely, ATOH8 expression may enhance
the sensitivity of liver cancer cells to chemotherapy.

on understanding the dynamics of genes and proteins
during the evolution of drug-resistance through decisive
stages. Results from proteomics and transcriptomics
analyses suggested that each cell state transition is
generally marked with an unique cascades of signaling
molecules and unusual stem cell markers, such as CD36,
CD68, CD70 and heat shock proteins. Dr. Pillai suggested
that increased intracellular inflammatory signaling
simultaneously triggers autophagy dependent damage
clearance during long cell cycle arrest while heat shock
proteins and ubiquitin dependent pathway subsequently
ensures emergence of few cells with altered intracellular
protein network in delayed manner.
Professor Li Zhu from the Shanghai Jiaotong
University School of Medicine shared her experience in
stratifying breast cancer patients based on the “primary
prognostic predictors” such as tumor size, grade and
lymph node status, HER2, estrogen receptor, and
progesterone receptor (PgR) at the time of diagnosis.
Dr. Zhu also discussed the evolution of the “secondary
prognostic assays” which are expected to provide a
better predictions of clinical outcome than the traditional
clinical and pathological standards, because around
50% of all recurrences in ER+ cancers develop after
5 years, Dr. Zhu discussed the prognostic value of the
newer tests (Prosigna™ , EndoPredict™ and BCI™) for
late recurrences and identify specific group of patients
might benefit from extended endocrine therapy. Dr.
Zhu also shared the excitement associated with a recent
gene expression-based outcome predictor for adjuvant
chemotherapy and endocrine therapy sensitivity as the first
example of a tertiary residual risk predictor. In brief, Dr.
Zhu highlighted the significance of step-wise utilization of
primary, secondary and tertiary prognostic endpoints in the
treatment of breast cancer.

Big Data

Proteomics and Epigenetics

Professor Stefan Knapp from the University
of Oxford and Johann Wolfgang Goethe-University
discussed recent developments targeting bromodomains.
In the first section of the talk he provided an overview on
BET bromodomain inhibitors and the potential of these
protein interaction inhibitors in the oncology field [8,
9]. After this introduction he selected examples of nonBET bromodomain inhibitors in particular inhibitors that
target bromodomains present in SMARCA2/4 as well
as CBP/EP300. Both of these bromodomain inhibitors
are non-toxic to cancer cells. However, inhibition of
SMARCA2/4 bromodomains mediates expression of
key genes important for certain cell differentiation.
Interestingly, CBP/EP300 bromodomain inhibition affects
leukemia inducing cells (LICs) resulting in differentiation
and induction of apoptosis. In addition, CBP/EP300
bromodomain inhibitors are synergistic with doxorubicine
as well as BET inhibition suggesting that combination

Professor M. Radhakrishna Pillai from the Rajiv
Gandhi Centre for Biotechnology highlighted the role
of chemotherapy-induced emergence of drug resistance
cells with cancer stem cells properties in controlling the
therapeutic response versus failure. Dr. Pillai’s approach
was focused on studying the biology of persister cells surviving cell population after extremely high doses of
chemotherapy. It appears that persister cells exhibit an
increased autophagy and mitophagy as well as constitutive
activation of redox masters. Dr. Pillai shared data
establishing a quick shift in low proteasome activity at the
onset of autophagy and that chronic mitophagy facilitate
long term survival of resistant cells in low nutrient
condition and intracellular protein stress. Over time, this
population led to the generation cell populations with
heterogeneous ROS and distinct tumorigenic potential.
The second part of Dr. Pillai’s presentation was focused
www.impactjournals.com/Genes&Cancer
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trigger perioperative hypoxia. Dr. Dutt started with the
study design involving transcriptomic analyses of breast
tumors collected at distinct presumed hypoxic stages. He
also discussed the status of various regulatory networks
as emerged from the study. Dr. Dutt finished his lecture
by suggesting that targeting one or more of these nodules
during perioperative surgery may influence the clinical
outcome of breast cancer patients undergoing surgical
intervention.

studies or CBP/BET dual inhibitors may lead to better
efficacy in leukemia and potentially in other cancers.
Dr. Masahiro Sugimoto from the Institute for
Advanced Biosciences at Keio University presented his
work about the development of a mathematical algorithm
which could be used to predict the outcome of neoadjuvant
chemotherapy for HER2 positive breast cancer and how
he got involved in such research questions. Neoadjuvant
chemotherapy is generally used the reduction of tumor
size, and pathological complete response (pCR) postneoadjuvant chemotherapy is viewed as a prognosis
marker. Dr. Sugimoto highlighted the poor predictive
accuracy of pCR in neoadjuvant setting using trastuzumab,
and the need to develop a novel mathematical model based
on artificial intelligence to realize better accuracy than
conventional statistical approaches. He also discussed the
steps taken to validate the model using a dataset involving
776 breast cancer patients. He shared his hope that such
a model would contribute to the personalization of the
neoadjuvant chemotherapy treatments.

Conclusions
In summary, the conference was two full days of
scientific celebration of ideas and discussions of recent
advances in cancer genomic biology, therapeutics, and
treatment. Most of the questions and answers segments
were dominated by discussing how to take forward
the findings to the bedside and what should be done to
maintain the momentum gained at this and preceding four
meetings. Another distinctive feature of the meeting was
an active participation of medical educators and professors
and medical students. It was not uncommon to witness
questions from practicing clinicians and educators relating
the scientific presentations with their teaching and training
responsibilities. Keeping in-line of the past four meetings,
issues surrounding the value of tumor heterogeneity
and transcriptome and how to design start anti-cancer
agents echoed throughout the conference. As expected,
scientific sessions started with an overview of the field,
what’s emerging, what are the current limitations, and
how one can take the research question forward in the
overall interest of cancer biology and treatment. Finally,
in the closing remarks by conference Co-Chairs, the group
discussed about the nature of feasible activities within the
changing framework of consortium members and use of
tele-medicine for the benefits of cancer patients.

Hormone Expression Profiles
Professor Louis Chow from the Macau University of
Science, Technology and Organisation for Oncology and
Translational Research and Jiujiang University discussed
emerging targeted treatment modalities for breast cancer
[10]. He started by comparing the traditional, clinical
risk factors for breast cancer patients with several novel
molecular arrays that may help determine recurrence risk.
Dr. Chow provided an overview on the current different
risk-arrays, largely for luminal breast tumors. PAM50™, Oncotype DX™, Mammaprint™, BreastPRS™,
EndoPredict™ and Mammostrat™ are all breast cancer
risk assessment arrays and Dr. Chow inter-compared these
different arrays for gene panels, methodology, timing and
patient selection to optimise array utilization. Dr. Chow
continued to discuss breast cancer subtypes, noting that
Triple Negative Breast Cancers (TNBC) have recently
been further sub classified into six distinctly separate
subtypes, responsive to different classes of drugs. TNBC
should no longer be regarded as one molecular group.
Dr. Chow continued his presentation by highlighting
the need of better methods to monitor tumor molecular
changes over time and discussed the liquid biopsy, thereby
stressing tumor heterogeneity. He ended his presentation
by seeking a better bi-directional interactions between
clinicians and laboratory scientists and continuing the
development of technologies such as liquid biopsies.
Dr. Amit Dutt from the Tata Memorial Centre
discussed the nature of genomic and molecular changes
associated with the events in the surrounding tissues of
breast cancer patients undergoing surgery. The study
was undertaken to address a broader question about the
transcriptomic status of breast tumors in patients who opt
to undergo surgical intervention which is also known to
www.impactjournals.com/Genes&Cancer
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